Synthesis and Characterization of HE-24.8: A Polymeric Contrast Agent for Magnetic Resonance Angiography
- 23 December 2005
- journal article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 17 (1) , 42-51
- https://doi.org/10.1021/bc0501909
Abstract
The physical and biological properties of a water-soluble polymeric contrast agent based on a complex of N-(2-hydroxypropyl)methacrylamide copolymer with gadolinium (HE-24.8) were investigated, and its potential for experimental magnetic resonance (MR) angiography was assessed. Relaxivities of Gd-DTPA-BMA, Gd-DTPA-HSA (human serum albumin), and HE-24.8 were determined at 1.5 T. Thermic stability and biocompatibility of HE-24.8 were assessed in vitro and by analyzing kinetics and organ distribution in rats for up to 2 weeks. For comparison, HE-24.8- and Gd-DTPA-HSA-enhanced micro-MR angiographies of brain, chest, and subcutaneous tumors in rats were performed. T1 relaxivity of HE-24.8 (21.3 ± 1.1 mM-1 s-1) was 5-fold higher than that of Gd-DTPA-BMA (4.1 ± 0.1 mM-1 s-1) and twice as high as that of Gd-DTPA-HSA (12.4 ± 0.2 mM-1 s-1). Varying the molecular weight of the polymer (15−46 kDa) did not significantly change the T1 relaxivity. In rats, 20 and 10% of the injected dose of HE-24.8 was detected at 24 and 168 h postinjection, respectively. Upon a relatively rapid initial renal clearance, no specific retention in any organ was noted, with some exception for the reticulo-endothelial system. No measurable release of gadolinium from the polymer−Gd complex or cell toxicity was observed during its incubation in aqueous environment. Excellent display of rat and tumor vascularization was achieved with Gd-DTPA-HSA and HE-24.8; however, contrast of vessels was higher in HE-24.8-enhanced scans. HE-24.8 is considered a macromolecular contrast agent highly suited for experimental MR studies.Keywords
This publication has 21 references indexed in Scilit:
- Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weightsJournal of Magnetic Resonance Imaging, 2004
- Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albuminMagnetic Resonance in Medicine, 2003
- High-resolution three-dimensional MR angiography of rodent tumors: Morphologic characterization of intratumoral vasculatureJournal of Magnetic Resonance Imaging, 2003
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- In vivo mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (Kps) in solid tumors using a macromolecular contrast agent: Correlation with histology and ultrastructureInternational Journal of Cancer, 2003
- Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directionsJournal of Magnetic Resonance Imaging, 2002
- Magnetic Resonance Imaging of Nude Mice With Heterotransplanted High-Grade Squamous Cell CarcinomasInvestigative Radiology, 2002
- HPMA Copolymers Platinates Containing Dicarboxylato Ligands. Preparation, Characterisation and In Vitro and In Vivo EvaluationJournal of Drug Targeting, 2002
- Neuroimaging: do we really need new contrast agents for MRI?European Journal of Radiology, 2000
- Polymeric drugs based on conjugates of synthetic and natural macromoleculesJournal of Controlled Release, 2000